Former Teva chief takes chairmanship at Sun; NYSE probes spike in KV Pharma trading;

 @FiercePharma:  Endo's lobbying yields a provision in House user-fee bill that could protect its Lidoderm patch--NYTMore | Follow @FiercePharma

> Sun Pharmaceuticals has recruited former Teva ($TEVA) CEO Israel Makov to serve as chairman, aiming to take advantage of his experience "globalizing businesses successfully," Managing Director Dilip Shanghvi said. Report

> KV Pharmaceutical ($KV-A) stock trading went through the roof Friday, with more than 2.9 million shares changing hands; the New York Stock Exchange is investigating. Story

> Endo Health Solutions ($ENDP) and Watson Pharmaceuticals ($WPI) settled their dispute over a generic version of Endo's Lidoderm patch, allowing Watson to launch a copy in 2013 under a royalty-and-supply agreement. News

> A $5.8 million pilot program in Hong Kong will subsidize expensive cancer drugs, with help from a $3.2 million contribution from GlaxoSmithKline ($GSK). Item

> In the focus on a genetic variant that may limit response to Sanofi ($SNY) and Bristol-Myers Squibb's ($BMY) bloodthinner Plavix, another cause of poor drug performance--noncompliance--might be overlooked. Article

> A federal task force has examined more data on hormone therapy for women and once again recommended against their use in those already past menopause. Story

> One in 10 prescriptions in Canada is written for off-label use, a study found. Report

Biotech News

 @FierceBiotech: California's CIRM votes to shift stem cell grants toward clinical development side. More | Follow @FierceBiotech

 @JohnCFierce: In fresh setback, Alnylam's most advanced drug flunks PhIIb RSV test. (Not what they need right now.) Item | Follow @JohnCFierce

 @RyanMFierce: 23andMe's Google ties make today's news of the gene patent less surprising. News | Follow @RyanMFierce

> Trial vets at Flexion claim PhIIb success with lead osteoarthritis drug. Article

> China readies plan to spur its booming biotech sector. Story

> Bristol-Myers pushes latest blockbuster cancer drug prospect into ASCO spotlight. Report

> BMS creates global cancer drug collaboration. More

Medical Devices News

 @FierceMedDev:  For Biosensors, stents and an acquisition helped drive a stellar FY2012. Report | Follow @FierceMedDev

 @MarkHFierce: Folks, there's still time to submit your nominations for the FierceMedicalDevices Fierce 15 private device developers. Survey | Follow @MarkHFierce

> Foundation Medicine launches innovative cancer diagnostic. Story

> GE opens $80 million research center in China. Article

> FDA cites J&J's McNeil-PPC unit for limp lubricants. News

> U.S. House ramps up for device tax repeal vote next week. More

Drug Delivery News

 @DamianFierce: Perhaps you can have too much of a good thing. Penn researchers say too many nanocarriers render treatments ineffective: Story | Follow @DamianFierce

> MIT develops needle-free jet injector. More

> Delivery firm seeks $3M for transdermal platform. Story

> West Pharma looks to cash in on biosimilar delivery. Report

> IntelGenx eyes FDA nod with anti-migraine film results. Item

Biomarkers News

> Biomarkers help select the most fertile donors. News

> The economics and value of genetic biomarkers. Story

> Fitness as a biomarker in breast cancer. More

> Bile duct biomarker screening for fluke-linked cancer. Article

And Finally... Aspirin and similar drugs may protect against skin cancer, researchers said. Report